Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia.

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Therapeutic Use
  • Sponsors Intra-Cellular Therapies

    • Most Recent Events

    • 10 Mar 2009 Secondary endpoints 'Sleep efficiency' 'Total sleep time' has been met, according to an Intra-Cellular Therapeutics media release.
    • 10 Mar 2009 Final results have been reported in an Intra Cellular Therapies media release.
    • 13 Jan 2009 Primary endpoints 'Polysomnographic measures' and 'Wake time after sleep onset' have been met, according to an Intra-Cellular therapies media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top